Literature DB >> 8537260

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin.

F Doucet-Populaire1, C Truffot-Pernot, J Grosset, V Jarlier.   

Abstract

Clarithromycin has been reported to select clarithromycin resistant mutants of Mycobacterium avium complex (MAC) during treatment with clarithromycin in AIDS patients and beige mice. We selected resistant mutants in vitro at a frequency of 5 x 10(-9). Clarithromycin resistant strains of MAC isolated in AIDS patients and beige mice as well as derivatives selected in vitro had a unique pattern of acquired cross-resistance to macrolides and related antibiotics. In contrast, the pattern of resistance to non-macrolide antibiotics remained unchanged in clarithromycin resistant strains. A dramatic decrease in ribosome affinity for clarithromycin and erythromycin was found in clarithromycin resistant strains, but no mutation was found in the peptidyl domain of the 23S rRNA, indicating that another ribosomal modification is involved.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537260     DOI: 10.1093/jac/36.1.129

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.

Authors:  Aurélie Renvoisé; Florence Brossier; Eve Galati; Nicolas Veziris; Wladimir Sougakoff; Alexandra Aubry; Jérôme Robert; Emmanuelle Cambau; Vincent Jarlier; Christine Bernard
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

3.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice.

Authors:  C Jagannath; M R Emanuele; R L Hunter
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes.

Authors:  Jeng Yih Wu; Jae J Kim; Rita Reddy; W M Wang; David Y Graham; Dong H Kwon
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).

Authors:  Kevin A Nash
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells.

Authors:  M Wachsman; F M Hamzeh; H Saito; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex.

Authors:  Karolína Buriánková; Florence Doucet-Populaire; Olivier Dorson; Anne Gondran; Jean-Claude Ghnassia; Jaroslav Weiser; Jean-Luc Pernodet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.